The world's first innovative drug approved in China for delaying the progression of type 1 diabetes.

The official website of the National Medical Products Administration stated on September 5th that the world's first innovative drug for delaying the progression of type 1 diabetes - Teplizumab monoclonal antibody injection has been approved by the National Medical Products Administration of China. It can be used for children aged 8 and above and adult stage 1 type 1 diabetes patients. The innovative drug "Teplizumab monoclonal antibody" approved this time is a CD3-targeted monoclonal antibody. As early as June 2025, Teplizumab monoclonal antibody was prescribed for the first time in Asia at the Boao forum. Previous clinical studies and extended follow-up results have shown that treatment with Teplizumab monoclonal antibody for 14 days can delay the progression of stage 2 type 1 diabetes to stage 3 by nearly 3 years compared to the placebo group, avoiding irreversible damage caused by sudden severe illness to the body.